title: Correspondence.
authors: *Department of Ophthalmology, Mayo Clinic, Jacksonville, Florida †Department of Ophthalmology, University of North, Carolina, Chapel Hill, Chapel Hill, North Carolina ‡Charlotte Eye, Ear, Nose and Throat Associates, Charlotte, North Carolina §Department of Ophthalmology, Shinshu University, School of Medicine, Matsumoto, Japan ¶Department of Ophthalmology, Shiga University of Medical Science Seta Tsukinowacho, Otsu, Japan **Klinika Okulistyczna "Jasne Blonia," Lodz, Poland ††Srimati Kanuri Santhamma Centre for Vitreo-Retinal Diseases, Hyderabad Eye Research Foundation, Kallam Anji Reddy campus, L V Prasad Eye Institute, Hyderabad, India.
authors: Michael W
authors: MW
authors: Stewart
authors: Maurice B
authors: MB
authors: Landers
authors: David J
authors: DJ
authors: Browning
authors: Toshinori
authors: T
authors: Murata
authors: Masahito
authors: M
authors: Ohji
authors: Jerzy
authors: J
authors: Nawrocki
authors: Jay K
authors: JK
authors: Chhablani
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D003930:Diabetic Retinopathy / Q000628:therapy*; D005260:Female; D006801:Humans; D017075:Laser Coagulation; D008269:Macular Edema / Q000628:therapy*; D008297:Male; D000069579:Ranibizumab / Q000627:therapeutic use*; D014821:Vitrectomy
chemical_list: D020533:Angiogenesis Inhibitors; D000069579:Ranibizumab